Hims & Hers Health Inc. (NYSE:HIMS) shares are up during Monday's premarket session as the company has reportedly ended its legal feud with Novo Nordisk A/S (NYSE:NVO), paving the way for a new partnership involving weight-loss drugs.
Novo Nordisk Partners with Hims & Hers
Novo Nordisk has decided to sell its weight-loss drug through Hims & Hers' telehealth platform, following a lawsuit over patent violations regarding a compounded version of semaglutide products.
In February, Hims & Hers Health agreed to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers' international presence.
Hims and Hers 2026 Guidance Below Expectations
Hims & Hers Health reported fourth-quarter revenue of $617.82 million, falling short of analyst estimates of $619.22 million.
However, the company did beat earnings expectations with a reported 8 cents per share, surpassing estimates of 3 cents per share.
Hims & Hers also provided guidance for first-quarter revenue between $600 million and $625 million, which is below the analyst estimate of $653.12 million.
The company expects fiscal 2026 sales of $2.7 billion-$2.9 billion compared to the consensus of $2.74 billion, with adjusted EBITDA between $300 million and $375 million.
Mixed Technical Signals
The stock is currently trading 41.6% above its 20-day simple moving average (SMA) but is 30.4% below its 100-day SMA, indicating a mixed short-term and long-term technical picture.
Over the past 12 months, shares have decreased by 54.34% and are currently positioned closer to their 52-week lows than highs.
The RSI is at 30.87, which is considered neutral territory, while the MACD shows a value of -2.7530, with the signal line at -3.3415, indicating bullish momentum as the MACD is above the signal line.
This combination suggests that while the stock is not in an oversold condition, there is potential for upward movement.
- Key Resistance: $25.00
- Key Support: $15.00
Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $32.40. Recent analyst moves include:
- Barclays: Overweight (Lowers Target to $25.00) (Feb. 25)
- Morgan Stanley: Equal-Weight (Lowers Target to $21.00) (Feb. 25)
- Leerink Partners: Market Perform (Lowers Target to $17.50) (Feb. 24)
Benzinga Edge Ranks HIMS Mixed
Below is the Benzinga Edge scorecard for Hims & Hers Health, highlighting its strengths and weaknesses compared to the broader market:
- Value: Weak (Score: 5.75) — Trading at a steep premium relative to peers.
- Growth: Neutral (Score: 56.09) — Moderate growth potential in the telehealth sector.
- Momentum: Bearish (Score: 1.23) — Stock is showing very weak performance indicators.
The Verdict: Hims & Hers Health's Benzinga Edge signal reveals a mixed outlook. While the Value and Growth scores suggest potential for improvement, the weak Momentum score indicates that the stock is currently underperforming compared to the broader market.
Significant in Top ETFs
- SPDR Portfolio S&P 600 Small Cap ETF (NYSE:SPSM): 0.60% Weight
- SPDR S&P 600 Small Cap Growth ETF (based on S&P SmallCap 600 G (ARCA: SLYG): 1.17% Weight
- Vanguard S&P Small-Cap 600 Index Fund ETF (NYSE:VIOO): 0.64% Weight
HIMS Price Action: Hims & Hers Health shares were up 48.67% at $23.40 during premarket trading on Monday, according to Benzinga Pro data.
Image via Shutterstock
